8-K Announcements
6Material company update
May 26, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
May 1, 2026·SEC
Senti Biosciences, Inc.(SNTI)Earnings, Financials & Key Ratios
SNTI•NASDAQ
$1.01
Price updated Jul 7, 2026
AboutSenti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.Show more
- Revenue$22K
- EBITDA-$60M-8.9%
- Net Income-$61M-16.4%
- EPS (Diluted)-2.73+76.2%
- Gross Margin-16431.82%
- EBITDA Margin-273136.36%
- Operating Margin-289668.18%
- Net Margin-279263.64%
- ROE-393.35%-244.9%
SNTI Price & Volume
Senti Biosciences, Inc. (SNTI) stock price & volume — 10-year historical chart
Loading chart...
Senti Biosciences Faces Critical Liquidity Inflection Point
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity depletion risk
Key Thesis Takeaways
- Senti Biosciences remains a high-risk, pre-commercial biotechnology firm characterized by extreme cash burn and a rapidly deteriorating balance sheet.
- While the company continues to advance its proprietary gene circuit platform, the lack of sustainable revenue—evidenced by a nominal $22,000 in TTM revenue—leaves the firm entirely dependent on external financing.
- Investors should monitor the company's ability to manage its $19.1 million debt load against a shrinking cash position, as the current trajectory suggests significant dilution or asset divestiture risks are imminent.
Verdict Logic
the company's current ratio of 1.04 and the rapid erosion of total assets from $119.5 million in 2023Q4 to $38.2 million in 2026Q1 indicate an unsustainable capital structure.
SNTI Growth Metrics
Senti Biosciences, Inc. (SNTI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-43.85%
3 Years-81.15%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM5.92%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM83.95%
Return on Capital
10 Years-69.58%
5 Years-70.43%
3 Years-79.02%
Last Year-104.52%
SNTI Recent Earnings
Senti Biosciences, Inc. (SNTI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (67%)●Beat Revenue 3/12 qtrs (60%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.14+61.1%
$0.36
Rev
—
$20,534
Q2 2026
Mar 27, 2026Metric
Actual
Est
EPS
$0.38+11.6%
$0.43
Rev
$22,000-97.8%
$1M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.69-16.9%
$0.59
Rev
—
$250,000
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.56+37.8%
$0.90
Rev
—
$500,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.14vs $0.36+61.1% | —vs $20,534 |
| Q2 2026 | Mar 27, 2026 | $0.38vs $0.43+11.6% | $22,000vs $1M-97.8% |
| Q4 2025 | Nov 13, 2025 | $0.69vs $0.59-16.9% | —vs $250,000 |
| Q3 2025 | Aug 7, 2025 | $0.56vs $0.90+37.8% | —vs $500,000 |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Senti Biosciences, Inc. (SNTI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.01 | $31.28M | -0.37 | — | -279263.64% | -393.35% | — | |
| $3.02 | $352.01M | -2.63 | -51.24% | -2056.79% | -58.89% | — | |
| $60.77 | $5.86B | -9.39 | -89.97% | -13856.54% | -30.88% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — | |
| $0.07 | $30.66M | -0.17 | -31.57% | -356.89% | — | — |
Compare SNTI vs Peers
Senti Biosciences, Inc. (SNTI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SNTI SEC Filings & Documents
Senti Biosciences, Inc. (SNTI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SNTI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SNTI Frequently Asked Questions
Senti Biosciences, Inc. (SNTI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Senti Biosciences, Inc.'s revenue?
Senti Biosciences, Inc. (SNTI) reported $0.0M in revenue for fiscal year 2025. This represents a 55% decrease from $0.1M in 2019.
Is SNTI profitable?
Senti Biosciences, Inc. (SNTI) reported a net loss of $51.5M for fiscal year 2025.
Dividend & Returns
What is SNTI's return on equity?
Senti Biosciences, Inc. (SNTI) has a return on equity (ROE) of -393.4%. Negative ROE indicates the company is unprofitable.
What is Senti Biosciences, Inc.'s free cash flow?
Senti Biosciences, Inc. (SNTI) had negative free cash flow of $37.1M in fiscal year 2025, likely due to heavy capital investments.